Keyphrases
Melanoma
86%
Metastatic Melanoma
81%
Glioblastoma
59%
Newly Diagnosed Glioblastoma
59%
Immune Checkpoint Inhibitors
57%
Temozolomide
53%
Radiation Therapy
51%
Pembrolizumab
45%
Tumor
44%
Progression-free Survival
42%
Targeted Therapy
35%
Recurrent Glioblastoma
34%
BRAF Inhibitor (BRAFi)
33%
Disulfiram
33%
Overall Survival
30%
Cutaneous Squamous Cell Carcinoma (cSCC)
27%
Circulating Tumor DNA (ctDNA)
27%
PARP Inhibitor (PARPi)
27%
Phase II Study
26%
Phase II Trial
25%
Photothermal Therapy
25%
Homologous Recombination Deficiency
25%
Phase 1/2 Study
25%
Concurrent Radiation
25%
BRAF mutant
25%
MEK Inhibitor (MEKi)
22%
BRAFV600
19%
Trametinib
19%
Dabrafenib
19%
Treatment Strategy
19%
Disease Progression
19%
Clinical Outcomes
18%
C-X-C Chemokine Receptor Type 4 (CXCR4)
16%
Doxorubicin
16%
Nivolumab
16%
Copy number Variation
16%
Meningioma
16%
Talimogene Laherparepvec (T-VEC)
15%
Novel Therapeutics
15%
Adjuvant Temozolomide
14%
Granulocyte Colony-stimulating Factor (G-CSF)
14%
Remission
14%
Immune Checkpoint Inhibitor Therapy
14%
Advanced Melanoma
14%
Cancer Cells
12%
Hematopoietic Stem Cells
12%
Hematopoietic Stem Cell Mobilization
12%
Melanoma Cells
12%
Point mutation
12%
Rapid Response
12%
Medicine and Dentistry
Melanoma
100%
Immunotherapy
86%
Immune Checkpoint Inhibitor
54%
Metastatic Melanoma
54%
Glioblastoma
51%
Pembrolizumab
45%
Neoplasm
33%
Circulating Tumor DNA
30%
Skin Carcinoma
27%
Radiation Therapy
27%
MEK Inhibitor
26%
Targeted Therapy
25%
Homologous Recombination
25%
Melanoma Skin Cancer
23%
PARP Inhibitor
23%
Cancer
20%
Ganglioglioma
19%
Temozolomide
17%
Immunity
17%
Talimogene Laherparepvec
16%
Hematopoietic Cell
16%
Progression Free Survival
15%
Systemic Therapy
14%
Diseases
13%
Disease Exacerbation
12%
Overall Survival
12%
Monotherapy
12%
Immune Checkpoint Blockade
11%
Stem Cell Mobilization
11%
Poly ADP Ribose Polymerase
10%
Melanoma Cell
10%
Malignant Neoplasm
10%
Trametinib
10%
Dabrafenib
10%
Oncolytic Virus
10%
Stereotactic Body Radiation Therapy
9%
Meta-Analysis
9%
DNA Determination
9%
Combined Therapy
9%
Autoantibodies
8%
Retinopathy
8%
Oligoastrocytoma
8%
Salvage Therapy
8%
Olaparib
8%
Isoetarine
8%
Oligodendroglioma
8%
Leukemia
8%
Whole Body Radiation
8%
Merkel Cell Carcinoma
8%
Germ Cell
8%
Pharmacology, Toxicology and Pharmaceutical Science
Glioblastoma
76%
Melanoma
64%
Temozolomide
51%
Neoplasm
45%
Immunotherapy
35%
Progression Free Survival
34%
Disulfiram
33%
Overall Survival
27%
Immune Checkpoint Inhibitor
25%
Malignant Neoplasm
21%
Metastatic Melanoma
19%
Pembrolizumab
18%
Skin Carcinoma
18%
Circulating Tumor DNA
16%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
16%
Bevacizumab
13%
Chemotherapy
12%
Monotherapy
12%
Cutaneous Melanoma
11%
Placebo
10%
Systemic Treatment
9%
Oncolytic Virus
9%
Diseases
9%
Adverse Event
9%
Chemoradiation Therapy
9%
Phase II Trials
8%
Hydroxychloroquine
8%
Cetuximab
8%
Meningioma
8%
Nivolumab
8%
Trametinib
8%
Dabrafenib
8%
Isocitrate Dehydrogenase
8%
Doxorubicin
8%
Brain Metastasis
8%
Solid Malignant Neoplasm
8%
Phosphotransferase
8%
Astrocytoma
8%
Observational Study
8%
Oligodendroglioma
8%
Ibrutinib
8%
Focal Adhesion Kinase
8%
Granulocyte Colony Stimulating Factor
8%
Leukemia
8%
Chemokine Receptor CXCR4 Antagonist
8%
Autoimmune Hemolytic Anemia
8%
Talimogene Laherparepvec
8%
Interleukin 2
8%
Messenger RNA
8%
Janus Kinase 1
8%